Meigene completed 167 million RMB rounds of financing

The main target of the Xiamen-based company is genetic testing for end consumers and clinics, targeting health internventions, drug development etc.

China Bio news release, October 26, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny